Project Grant R34DA067031
Award Date 9/1/26
Completion Date 7/31/29
Dollars Obligated $296K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $1,593,298 under Project Grant R01DA066715 on July 1, 2026, to evaluate health impacts of municipal interventions addressing homelessness and opioid use disorder. The recipient will characterize longitudinal trends in overdose, health service use, and housing engagement among people experiencing homelessness from 2015 through 2024 across major policy actions; assess associations between homelessness programs and...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $1,106,433 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, for development and evaluation of a universal overdose prevention intervention delivered in primary care settings. Boston Medical Center will develop and pilot an evidence-based intervention designed to increase youth awareness of fentanyl and emerging drugs in the drug supply, knowledge of overdose risk reduction...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $870,407 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on pre-release Medicaid effects on youth experiences related to substances (PRIME Years). The project addresses barriers to behavioral health service access for youth ages 16–25 following incarceration, a population with 36–84% prevalence of substance use history. The research examines Medicaid...
- Federal Grant Award Summary Boston Medical Center Corporation received a $356,630 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 1, 2025, with completion scheduled for August 31, 2027. The grant supports immune profiling research investigating how drug abuse impacts antibody responses in people living with HIV (PLWH), particularly among people who use substances and live with HIV (PWUSH). The...
- The National Institute on Drug Abuse awarded Massachusetts General Hospital $197,640 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a four-year project examining the clinical impact and cost-effectiveness of integrating infectious disease care into rapid-access substance use bridge clinics. The research addresses the syndemic of substance use disorder and infections among people who inject drugs, who face elevated risk of overdose, acute bacterial...
- The National Institute on Drug Abuse awarded The General Hospital Corporation (Massachusetts General Hospital) $453,750 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026. The award funds a mixed-methods examination of adolescent overdose and return to high-risk drug use after inpatient addiction treatment. The research leverages an existing longitudinal dataset of adolescents aged 12–19 followed for 12 months after treatment discharge, 52 percent of whom...
- The National Institute on Drug Abuse awarded Trustees of Boston University $193,751 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a career development research initiative examining quality of care in outpatient substance use disorder treatment facilities. The award funds a five-year training and research plan designed to develop the principal investigator as an independent substance use disorder services researcher. The research uses a novel...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $231,600 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support scholarships and speaker fees for the annual Academic Consortium of Criminal Justice Health (ACCJH) Conference. The funding supports a 2-day conference that convenes clinicians, researchers, and people with firsthand experience of incarceration to discuss emerging topics at the intersection of incarceration...
- The National Institute on Drug Abuse awarded Massachusetts General Hospital $953,616 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate machine learning prediction models for opioid overdose mortality and all-cause mortality among individuals experiencing homelessness, and to characterize treatment trajectories associated with mortality outcomes using 20 years of clinical and mortality data from a cohort in Boston. The project will employ an...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $100,228 on January 7, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal study examining how dynamic housing status affects healthcare utilization among people who inject drugs living with and without HIV. The research characterizes longitudinal housing trajectories among people who inject drugs in Baltimore, Maryland, and assesses the causal relationship between housing...